Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
PEN's Cash to Debt is ranked higher than
76% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. PEN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PEN' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity to Asset 0.87
PEN's Equity to Asset is ranked higher than
88% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. PEN: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
PEN' s Equity to Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.87 Max: 0.88
Current: 0.87
-0.1
0.88
Interest Coverage No Debt
PEN's Interest Coverage is ranked higher than
75% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 69.16 vs. PEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PEN' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.5 Max: No Debt
Current: No Debt
N/A
No Debt
Z-Score: 39.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 2.27
PEN's Operating margin (%) is ranked lower than
52% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. PEN: 2.27 )
Ranked among companies with meaningful Operating margin (%) only.
PEN' s Operating margin (%) Range Over the Past 10 Years
Min: -1.27  Med: 0.57 Max: 2.4
Current: 2.27
-1.27
2.4
Net-margin (%) 1.54
PEN's Net-margin (%) is ranked higher than
50% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. PEN: 1.54 )
Ranked among companies with meaningful Net-margin (%) only.
PEN' s Net-margin (%) Range Over the Past 10 Years
Min: 1.54  Med: 3.2 Max: 4.61
Current: 1.54
1.54
4.61
ROE (%) 1.03
PEN's ROE (%) is ranked higher than
50% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. PEN: 1.03 )
Ranked among companies with meaningful ROE (%) only.
PEN' s ROE (%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.03
Current: 1.03
0
1.03
ROA (%) 1.44
PEN's ROA (%) is ranked higher than
54% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: -0.39 vs. PEN: 1.44 )
Ranked among companies with meaningful ROA (%) only.
PEN' s ROA (%) Range Over the Past 10 Years
Min: 1.44  Med: 4.05 Max: 5.76
Current: 1.44
1.44
5.76
ROC (Joel Greenblatt) (%) 6.55
PEN's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 4.23 vs. PEN: 6.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3.24  Med: 2.01 Max: 7.26
Current: 6.55
-3.24
7.26
» PEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

PEN Guru Trades in Q3 2015

Paul Tudor Jones 6,700 sh (New)
PRIMECAP Management 100,000 sh (New)
Chuck Royce 1,000 sh (New)
RS Investment Management 115,701 sh (New)
» More
Q4 2015

PEN Guru Trades in Q4 2015

PRIMECAP Management 101,300 sh (+1.30%)
Chuck Royce 1,000 sh (unchged)
Paul Tudor Jones Sold Out
RS Investment Management Sold Out
» More
Q1 2016

PEN Guru Trades in Q1 2016

Chuck Royce 1,000 sh (unchged)
PRIMECAP Management 86,800 sh (-14.31%)
» More
Q2 2016

PEN Guru Trades in Q2 2016

Paul Tudor Jones 5,500 sh (New)
Jim Simons 158,600 sh (New)
Chuck Royce 1,000 sh (unchged)
PRIMECAP Management 84,600 sh (-2.53%)
» More
» Details

Insider Trades

Latest Guru Trades with PEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:GMED, NAS:WMGI, OTCPK:NHNKY, OTCPK:SHWGY, NYSE:NVRO, NAS:MASI, NAS:LIVN, NAS:ZLTQ, OTCPK:NISOF, NAS:NUVA, OTCPK:GGNDF, OTCPK:EKTAF, NAS:IART, OTCPK:IOBCF, NAS:BABY, NAS:CYNO, OTCPK:DGWPF, NAS:INGN, NAS:CNMD, NAS:LDRH » details
Traded in other countries:0P8.Germany,
Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures.

Penumbra Inc was incorporated in 2004 as a Delaware corporation under the name Penumbra. It is an interventional therapies company that designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company sells its products to hospitals through its salesforce, as well as through distributors. It sells its products through direct sales organization in the United States, Europe, Canada and Australia. Its products include Penumbra System, ACE, Penumbra Coil 400, Penumbra SMART COIL, LIBERTY Stent, Apollo System, Ruby Coil and Indigo System. The Company competes with manufacturers and distributors of neurovascular and peripheral vascular medical devices. Its competitors are Boston Scientific, Johnson & Johnson, Medtronic, Stryker and Terumo. Its products are medical devices subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FD&C Act), and its implementing regulations, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries under other statutes and regulations.

Ratios

vs
industry
vs
history
P/E(ttm) 589.51
PEN's P/E(ttm) is ranked lower than
99% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. PEN: 589.51 )
Ranked among companies with meaningful P/E(ttm) only.
PEN' s P/E(ttm) Range Over the Past 10 Years
Min: 462.67  Med: 502.21 Max: 619.17
Current: 589.51
462.67
619.17
PE(NRI) 589.51
PEN's PE(NRI) is ranked lower than
99% of the 166 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. PEN: 589.51 )
Ranked among companies with meaningful PE(NRI) only.
PEN' s PE(NRI) Range Over the Past 10 Years
Min: 462.67  Med: 502.21 Max: 619.17
Current: 589.51
462.67
619.17
P/B 8.84
PEN's P/B is ranked lower than
88% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. PEN: 8.84 )
Ranked among companies with meaningful P/B only.
PEN' s P/B Range Over the Past 10 Years
Min: 4.83  Med: 6.48 Max: 9.32
Current: 8.84
4.83
9.32
P/S 5.63
PEN's P/S is ranked lower than
71% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.21 vs. PEN: 5.63 )
Ranked among companies with meaningful P/S only.
PEN' s P/S Range Over the Past 10 Years
Min: 3.48  Med: 4.29 Max: 5.92
Current: 5.63
3.48
5.92
EV-to-EBIT 398.10
PEN's EV-to-EBIT is ranked lower than
99% of the 161 Companies
in the Global Medical Devices industry.

( Industry Median: 22.46 vs. PEN: 398.10 )
Ranked among companies with meaningful EV-to-EBIT only.
PEN' s EV-to-EBIT Range Over the Past 10 Years
Min: 81.4  Med: 332.55 Max: 810.2
Current: 398.1
81.4
810.2
EV-to-EBITDA 281.01
PEN's EV-to-EBITDA is ranked lower than
99% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 18.25 vs. PEN: 281.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
PEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 52.7  Med: 234.75 Max: 412.4
Current: 281.01
52.7
412.4
Current Ratio 8.09
PEN's Current Ratio is ranked higher than
90% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. PEN: 8.09 )
Ranked among companies with meaningful Current Ratio only.
PEN' s Current Ratio Range Over the Past 10 Years
Min: 4.4  Med: 7.78 Max: 8.81
Current: 8.09
4.4
8.81
Quick Ratio 5.96
PEN's Quick Ratio is ranked higher than
86% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. PEN: 5.96 )
Ranked among companies with meaningful Quick Ratio only.
PEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.75  Med: 5.74 Max: 7.03
Current: 5.96
2.75
7.03
Days Inventory 273.04
PEN's Days Inventory is ranked lower than
81% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 133.25 vs. PEN: 273.04 )
Ranked among companies with meaningful Days Inventory only.
PEN' s Days Inventory Range Over the Past 10 Years
Min: 258.85  Med: 288.92 Max: 318.98
Current: 273.04
258.85
318.98
Days Sales Outstanding 55.39
PEN's Days Sales Outstanding is ranked higher than
70% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 68.90 vs. PEN: 55.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
PEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.71  Med: 54.36 Max: 55.39
Current: 55.39
53.71
55.39
Days Payable 19.41
PEN's Days Payable is ranked lower than
90% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. PEN: 19.41 )
Ranked among companies with meaningful Days Payable only.
PEN' s Days Payable Range Over the Past 10 Years
Min: 15.46  Med: 17.78 Max: 20.09
Current: 19.41
15.46
20.09

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 21.24
PEN's Price/Net Cash is ranked lower than
60% of the 94 Companies
in the Global Medical Devices industry.

( Industry Median: 16.20 vs. PEN: 21.24 )
Ranked among companies with meaningful Price/Net Cash only.
PEN' s Price/Net Cash Range Over the Past 10 Years
Min: 9.33  Med: 13.42 Max: 22.28
Current: 21.24
9.33
22.28
Price/Net Current Asset Value 9.81
PEN's Price/Net Current Asset Value is ranked lower than
63% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 7.35 vs. PEN: 9.81 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PEN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 5.48  Med: 7.04 Max: 10.29
Current: 9.81
5.48
10.29
Price/Tangible Book 8.88
PEN's Price/Tangible Book is ranked lower than
75% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 4.28 vs. PEN: 8.88 )
Ranked among companies with meaningful Price/Tangible Book only.
PEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.23  Med: 6.43 Max: 9.31
Current: 8.88
5.23
9.31
Price/Median PS Value 1.32
PEN's Price/Median PS Value is ranked lower than
69% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. PEN: 1.32 )
Ranked among companies with meaningful Price/Median PS Value only.
PEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.87  Med: 1.01 Max: 1.38
Current: 1.32
0.87
1.38
Price/Graham Number 15.25
PEN's Price/Graham Number is ranked lower than
96% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. PEN: 15.25 )
Ranked among companies with meaningful Price/Graham Number only.
PEN' s Price/Graham Number Range Over the Past 10 Years
Min: 12.82  Med: 12.82 Max: 15.99
Current: 15.25
12.82
15.99
Earnings Yield (Greenblatt) (%) 0.20
PEN's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. PEN: 0.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 0.3 Max: 1.2
Current: 0.2
0.1
1.2

More Statistics

Revenue (TTM) (Mil) $227.9
EPS (TTM) $ 0.12
Short Percentage of Float4.70%
52-Week Range $35.32 - 77.25
Shares Outstanding (Mil)31.05

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 255 313 374
EPS ($) -0.15 0.22 0.50
EPS w/o NRI ($) -0.15 0.22 0.50
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NYSE:PEN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Penumbra, Inc. Announces Participation at Upcoming Investor Conferences Aug 18 2016
Penumbra, Inc. Announces Participation at Upcoming Investor Conferences Aug 18 2016
PENUMBRA INC Financials Aug 18 2016
Penumbra, Inc. :PEN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Penumbra (PEN) Q2 Earnings Top Estimates, Margins Down Aug 10 2016
Edited Transcript of PEN earnings conference call or presentation 9-Aug-16 8:30pm GMT Aug 09 2016
Penumbra posts 2Q profit Aug 09 2016
Penumbra posts 2Q profit Aug 09 2016
Penumbra, Inc. Reports Second Quarter 2016 Financial Results Aug 09 2016
PENUMBRA INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 09 2016
Penumbra, Inc. Reports Second Quarter 2016 Financial Results Aug 09 2016
Q2 2016 Penumbra Inc Earnings Release - After Market Close Aug 09 2016
Penumbra (PEN) to Report Q2 Earnings: What's in the Cards? Aug 02 2016
Randomized Penumbra 3D Trial of Next Generation Stent Retriever Meets Primary Endpoints Jul 27 2016
Randomized Penumbra 3D Trial of Next Generation Stent Retriever Meets Primary Endpoints Jul 27 2016
Traders laying down bets on Penn National Jul 26 2016
Penumbra Launches Newest Stroke Thrombectomy Technology ACE™68 Reperfusion Catheter at SNIS 2016 Jul 25 2016
Penumbra Launches Newest Stroke Thrombectomy Technology ACE™68 Reperfusion Catheter at SNIS 2016 Jul 25 2016
Penumbra Announces Key Events at Society of NeuroInterventional Surgery 2016 Meeting Jul 19 2016
Penumbra, Inc. Schedules Second Quarter 2016 Earnings Release and Conference Call for August 9, 2016... Jul 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)